NAV-002 (Navrogen): 一种FOLR1调节剂药物，由Navrogen, Inc. (Navrogen, Inc.)公司最早进行研发，目前全球最高研发状态为临床前，作用机制: FOLR1调节剂(叶酸受体α调节剂)，治疗领域: 肿瘤，在研适应症: 实体瘤，在研机构: Navrogen, Inc.。

002/25: 2025 active duty fund drive in support of the navy-marine corps relief society: 01/15/2025: 001/25: policy governing investigation and handling of formal sexual harassment complaints starting january 1, 2025, under 10 u.s.c. 1561: 01/10/2025

NAV-201 is a small-molecule compound that binds to CD16/Fc Receptor and activates NK cells, which go on to kill tumor cells (figure). NAV-201 can restore NK cell activity in the presence of immunosuppressive HIO factors.

NAV-002，由Navya Biologicals Pvt Ltd. (Navya Biologicals Pvt Ltd.)公司最早进行研发，目前全球最高研发状态为临床前，治疗领域: 免疫系统疾病，在研适应症: 自身免疫性疾病，在研机构: Navya Biologicals Pvt Ltd.。

NAV-002 (Navrogen): a FOLR1 modulators Drug, Initially developed by Navrogen, Inc., Now, its global highest R&D status is Preclinical, Mechanism: FOLR1 modulators (Folate receptor alpha modulators), Therapeutic Areas: Neoplasms, Active Indication: Solid …

Understand key drug designations in just a few clicks with Synapse. NAV-002, Initially developed by Navya Biologicals Pvt Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Immune System Diseases, Active Indication: Autoimmune Diseases, Active Org.: Navya Biologicals Pvt Ltd..

Shop official NAV vinyl, CDs, t-shirts, hoodies, longsleeves, accessories, digital music downloads, and more. OMW2 REXDALE, the long-awaited album new album from NAV, releases March 28. The official store of NAV.

了解Navya Biologicals Pvt Ltd. (Navya Biologicals Pvt Ltd.)公司的药物管线，治疗领域，技术平台，以及它的，疾病领域:肿瘤，免疫系统疾病，技术平台:小分子化药，药物:NAV-013，NAV-002，NAV-008，NAV-007，NAVOH-005。

Supersedes: Marine Notice NAV-002, dated 06/12 . The following changes have been included: It updates website and contact information for National Geospatial-Intelligence Agency. PURPOSE: This Notice serves as a reminder to all mariners that most of the navigational information

SYBIL STOCKDALE OMBUDSMAN OF THE YEAR AWARD.